Pharmacology for Nurses · Hypothalamus, Pituitary, and Adrenal Disorder Drugs

Growth Hormones and Suppressants

7 min read

On this page 9 sections

In 30 seconds
Why this matters
The college version
Eli explains
Worked example
Key takeaway
Check yourself
Study tools
Sources & references

In 30 seconds

Growth hormone (GH), produced by the cells of the anterior pituitary, is the body's main driver of linear growth and an important metabolic regulator. Its release is pulsatile — bursts occur especially during deep sleep, exercise, and stress — and is controlled by two hypothalamic signals: growth hormone–releasing hormone () stimulates release, while inhibits it. Most of GH's growth-promoting effects run indirectly through insulin-like growth factor 1 (), produced mainly by the liver in response to GH. Too little GH during childhood causes short stature; too much — usually from a pituitary adenoma — causes in childhood or in adulthood. This topic covers drugs for both problems: recombinant human growth hormone () replaces deficient GH, while GH suppressants — somatostatin analogues, a , and dopamine agonists — reduce excess GH activity. All content is educational; verify indications, doses, schedules, and monitoring against current references, the formulary, and prescriber orders.

Why this matters

Growth is a nursing assessment: Serial height, weight, and growth-chart trends are nursing data that often trigger the endocrinology referral.
Injection teaching is a nursing role: GH replacement is given by injection, often self-administered at home, so technique, site rotation, storage, and sharps safety are core teaching.
Adverse-effect surveillance: GH therapy can unmask glucose problems and fluid retention; suppressants carry GI, gallbladder, and glucose effects.
Exam logic: Distinguishing gigantism from acromegaly, and which drug replaces versus suppresses GH, are classic test questions.

The college version

Core Concepts

Growth hormone: the foreman of growth and metabolism

GH does two kinds of work. It drives linear growth — stimulating the growth plates (epiphyseal plates) of long bones, increasing protein synthesis, and promoting muscle and organ growth, much of it through IGF-1 — and it shapes metabolism, promoting fat breakdown (lipolysis), sparing protein, and raising blood glucose by opposing insulin. That is why GH excess or replacement therapy can disturb glucose tolerance. Two details matter for drug therapy:

Pulsatility: GH is released in bursts, so a single random level is hard to interpret; diagnosis relies on stimulation or suppression tests and on IGF-1, which reflects average output.
Dual control: GHRH is the accelerator and somatostatin the brake; drugs that mimic somatostatin become natural suppressants of GH excess.

GH deficiency and replacement therapy

GH deficiency presents as poor linear growth in children and altered body composition and fatigue in adults. Somatropin — recombinant human GH, identical in structure and action to the natural hormone — replaces the missing signal and restores IGF-1-driven growth and metabolic effects. Nursing points:

Administration: by injection (subcutaneous or intramuscular per product and order), with site rotation and technique taught before discharge.
Monitoring: growth velocity and chart position (children); IGF-1 as ordered; glucose, fluid balance, joint/muscle complaints.
Cautions: generally avoided in active cancer and certain acute critical illnesses — verify contraindications and screening against references and orders.

GH excess: gigantism and acromegaly

When a pituitary adenoma (or other cause) produces too much GH, the result depends on age. Before the growth plates fuse, excess GH drives gigantism — extreme tallness. After fusion, bones can no longer grow in length, so the excess causes acromegaly — thickening of facial features, enlarged hands and feet, overgrowth of internal organs — with metabolic effects (glucose intolerance, hypertension, joint disease). Treatment aims to lower GH and IGF-1 activity, via surgery, radiation, and/or medication.

GH suppressants: three ways to turn down the signal

Somatostatin analogues (octreotide, lanreotide): mimic the hypothalamus's natural brake on GH, binding somatostatin receptors on adenoma cells to reduce GH secretion (and often tumor growth). Given by injection (subcutaneous or long-acting intramuscular forms), they commonly cause GI upset (nausea, abdominal discomfort) and carry gallstone risk; because somatostatin also inhibits insulin and glucagon, glucose regulation can shift — monitoring is individualized.
GH receptor antagonist (pegvisomant): blocks GH from acting at its receptor, so IGF-1 falls even though GH levels may remain high. Monitoring therefore focuses on IGF-1 (the treatment target) and liver enzymes, which can rise.
Dopamine agonists (e.g., cabergoline): in some GH-secreting tumors, dopamine signaling inhibits GH release, so these oral drugs can lower GH and IGF-1, sometimes used alone or with other therapy.

Nursing considerations across both directions

Know which direction the drug works: somatropin raises GH activity; suppressants lower it. Mixing them up is a dangerous error.
Injectables need teaching: storage (often refrigerated), reconstitution, site rotation, sharps disposal, and never sharing pens or vials.
Monitor the metabolic ripple: glucose, weight, and fluid balance; with suppressants, GI symptoms and gallbladder-type pain; report as ordered.
Scope and setting: initiation, titration, and teaching responsibilities vary by licensure and institutional policy.

Common Confusions

Do Not Confuse	With	Difference
Gigantism	Acromegaly	Same GH excess; gigantism = before growth-plate closure (tall), acromegaly = after closure (thickening/enlargement)
Somatropin	Octreotide	Somatropin replaces GH (deficiency); octreotide suppresses GH (excess)
GHRH	Somatostatin	GHRH stimulates GH release; somatostatin inhibits it — accelerator vs. brake
Pegvisomant	Somatostatin analogues	Pegvisomant blocks the GH receptor (GH may stay high, IGF-1 falls); analogues reduce GH secretion itself
GH effect	Insulin effect	GH opposes insulin (raises glucose); the hormones pull metabolism opposite ways

Eli explains

The same idea, in plain words

Explain it like I’m 10

Growth hormone is like a construction foreman: it tells your bones and muscles to grow, and it makes your body burn fat and keep sugar available for energy. If the foreman is lazy, a child stays small — so we give a replacement foreman (somatropin). If he works too hard, a person grows too big — so we give drugs that calm him down (somatostatin analogues), block his megaphone so workers can't hear him (pegvisomant), or send a signal that makes him take a break (dopamine agonists).

Worked example

Patient A — GH deficiency. Eight-year-old Maya has fallen off her growth curve; testing confirms GH deficiency. Her prescriber orders somatropin, and the nurse's teaching covers: how to store and reconstitute the medication, rotate injection sites, and keep a growth log; why IGF-1 and blood glucose will be checked periodically; and what to report (joint pain, swelling, headaches). The nurse reinforces that growth takes time — a steady return to her growth channel, not a sudden jump.

Patient B — acromegaly. Mr. Okafor, an adult with acromegaly from a pituitary adenoma, starts a somatostatin analogue after surgery did not fully normalize his GH. The nurse explains: "This medicine mimics your body's natural brake on growth hormone, so your pituitary slows production." Teaching covers the injection schedule, GI side effects that often ease with time, gallstone-related pain to report, and follow-up IGF-1 testing. The nurse also checks blood pressure and glucose, because GH excess — and its treatment — affect both.

The contrast is the lesson: the same axis, two drugs moving the signal in opposite directions, nursing care identical in rigor (teach, monitor, report, verify) but opposite in target.

Key takeaways

GH axis: GHRH stimulates, somatostatin inhibits, and most growth effects run through IGF-1.
Somatropin = replacement; octreotide/lanreotide, pegvisomant, and dopamine agonists = suppression or blockade. Never confuse the two directions.
Gigantism vs. acromegaly: same cause (GH excess), different age — before vs. after growth-plate closure.
IGF-1 is the practical monitor: it reflects average GH output; plans follow prescriber orders.
GH therapy cautions: glucose tolerance can worsen; fluid retention and joint discomfort can occur; check cancer and critical-illness contraindications against current references.
Somatostatin analogues: GI upset, gallstone risk, and glucose effects.
Pegvisomant: GH may stay high while IGF-1 falls — the point is blocking action, not lowering GH; liver enzymes are monitored.
Teaching bundle for injectables: refrigeration, reconstitution, site rotation, sharps disposal, no sharing of devices.

Check yourself

5 review questions from the chapter. Try each one, then open the answer.

What are the two hypothalamic signals controlling GH, and which one does octreotide imitate?
Show answer
GHRH stimulates GH release and somatostatin inhibits it; octreotide is a somatostatin analogue, so it imitates the brake.
Why does GH excess cause gigantism in children but acromegaly in adults?
Show answer
Before growth plates fuse, excess GH drives length growth (gigantism); after fusion, bones cannot lengthen, so excess causes soft-tissue and bone thickening (acromegaly).
Which drug class replaces GH, and what route is it typically given by?
Show answer
Somatropin (recombinant human GH) replaces GH and is given by injection (subcutaneous or intramuscular per product and order).
A patient on pegvisomant asks why their GH level is still high. What is the correct explanation?
Show answer
Pegvisomant blocks GH at its receptor rather than lowering GH secretion, so GH can remain elevated while IGF-1 falls — IGF-1 is the treatment target.
Name three monitoring priorities for a person newly started on GH replacement therapy.
Show answer
Growth velocity/chart position (children), blood glucose, fluid balance/weight, and any joint, muscle, or headache complaints — all per the ordered plan.

Keep learning

Ready to build on this? Continue to the next lesson.

Study tools & related lessonsKey vocabulary · Related

Key vocabulary

Somatotroph: The anterior-pituitary cell that makes growth hormone
GHRH: Hypothalamic hormone that stimulates GH release
Somatostatin: Hypothalamic hormone that inhibits GH release
IGF-1: Insulin-like growth factor 1, made mainly in the liver in response to GH
Gigantism: GH excess before growth-plate fusion → extreme height
Acromegaly: GH excess after plate fusion → facial/bone/organ enlargement
Somatropin: Recombinant human growth hormone used for replacement
GH receptor antagonist: Drug (pegvisomant) that blocks GH at its receptor
Somatostatin analogue: Drug mimicking somatostatin to suppress GH secretion (octreotide, lanreotide)

Sources & references

openstax.org — Pharmacology

This lesson was adapted from the open educational references above; their licenses and attributions are preserved. See Copyright & Licensing.

Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.